Medicaid Information. The Business Associate acknowledges that all information related to the Children’s Health Insurance Program (CHIP) and the Medicaid program is confidential, disclosure must be restricted to purposes directly connected with the administration of the CHIP and Medicaid State Plans, and Business Associate must comply with 42 C.F.R. 431.300 et seq. and N.J.A.C. 10:49-9.7. See also 42 U.S.C. 1396a(a)(7) and N.J.S.A. 30:4D-7.g. The Business Associate shall ensure that all persons who will handle or have access under this Agreement to Medicaid or CHIP information will be advised of the confidentiality of the records and the safeguarding requirements.
Medicaid Information. (i) With respect to Product sold by Purchaser after the Commencement Date that bears an NDC number of Seller or any of Seller's Affiliates, Purchaser will deliver to Seller, within fifteen (15) days after the end of each Calendar Quarter or reporting period as designated by the Center for Medicare and Medicaid Services ("CMS") to include the following information: (a) on a quarterly basis, the "Best Price" (as defined under the Social Security Act, 42 USC § 1396r-8(c)(1)(C)) for all Product, identified by NDC number; and (b) on a monthly and quarterly basis, the average manufacturer price ("AMP") (as defined under the Social Security Act, 42 USC § 1396r-8(k)(1)) and the relevant AMP eligible sales dollar amounts, as well as the number of AMP eligible units for all of such Product, each identified by NDC number.
Medicaid Information. (a) With respect to Product sold by Prometheus after the Commencement Date that bears an NDC number of GSK or any of GSK's Affiliates, Prometheus will deliver to GSK, within fifteen (15) calendar days after the end of each Calendar Quarter or reporting period as designated by CMS to include the following information: (i) on a quarterly basis, the "best price" (as defined under the Social Security Act, 42 USC § 1396r-8(c)(1)(C)) for all Product, identified by NDC number; and (ii) on a monthly and quarterly basis, the average manufacturer price ("AMP") (as defined under the Social Security Act, 42 USC § 1396r-8(k)(1)) and the relevant AMP eligible sales dollar amounts, as well as the number of AMP eligible units for all of such Product, each identified by NDC number.
Medicaid Information. With respect to any of the Licensed Products sold by Distributor after the Commencement Date which bears an NDC number of MPL or any of MPL's Affiliates, Distributor shall deliver to MPL (and to the extent necessary for Distributor to comply with its Health Care Financing Administration reporting obligations, MPL shall deliver to Distributor), within fifteen (15) days after the end of each Calendar Quarter, the following information: the "best price" (as defined under the Social Security Act, 42 USC ss. 1396r-8(c)(1)(C)) for each of such Licensed Products, identified by NDC number, and the "average manufacturer price" (as defined under the Social Security Act, 42 USC ss. 1396r-8(k)(1)) and the sales dollar amount as well as the number of units for each of such Licensed Products, each identified by NDC number. Distributor agrees to provide to MPL any additional data or other information required for the calculation of the rebates contemplated in Section 3.05. Each party agrees that the other party may use all information described in this Section 3.06 in reporting to the Centers for Medicaid and Medicare Services.
Medicaid Information. With respect to any Product sold by JDS after the Closing Date which bears a National Drug Code number of Synthon or any of its Affiliates, JDS will deliver to Synthon, within fifteen (15) days after the end of each calendar quarter, the following information: (i) the “best price” (as defined under the Social Security Act, 42 U.S.C. §1396r-8(c)(1)(C) for each Product identified by National Drug Code number, (ii) the “average manufacturer price” (as defined under the Social Security Act, 42 U.S.C. §1396r-8(k)(1)) and the number of sales units and dollars for the Product, each identified by National Drug Code number and (iii) any penalties, including without limitation CPI based rebates. JDS agrees to provide to Synthon any additional data or other information regarding sales or pricing of the Product by JDS which Synthon requests as necessary for the calculation of the rebates contemplated in this Section. JDS agrees that Synthon may use all information described in this Section in Synthon’s reporting to the Center for Medicaid Services. Synthon shall provide to JDS the base date average manufacturer price and any assumptions with respect to the calculation thereof for the Products.
Medicaid Information. (a) With respect to any Product sold after the Effective Date which bears an NDC number of Merck (including without limitation Product sold by Merck as distributor for Guilford under the Transition Services Agreement), Merck shall determine, in accordance with all applicable laws, the *The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission. following information: (a) the "best price" (as defined under the Social Security Act, 42 U.S.C. Section 1396r-8(c)(1)(C)) for each formulation and package size of Product identified by NDC number, (b) the "average manufacturer price" (as defined under the Social Security Act, 42 U.S.C. Section 1396r-8(k)(1)) ("best price" and "average manufacturer price" are collectively referred to as the "Drug Pricing Information"), and (c) the number of sales units and net dollars including discounts and rebates for each product and class of trade, each identified by NDC number (the "Utilization Information"). Merck shall use the Drug Pricing Information and the Utilization Information in Merck's reporting to the Centers for Medicare and Medicaid Services. Guilford agrees to provide to Merck any additional data or other information in Guilford's possession regarding sales or pricing of the Product which Merck reasonably requests as necessary for the calculation of the rebates or the Drug Pricing Information or Utilization Information as contemplated in this Section 9.7 (including without limitation all relevant information about Product sold by Guilford and all discounts, price reductions and other applicable adjustments). Merck shall compute and report the Drug Pricing Information and Utilization Information in accordance with all applicable laws, including, but not limited to, 42 U.S.C. Section 1396r-8.
Medicaid Information. With respect to Product sold by Myogen after the Commencement Date that bears an NDC number of GSK or any of GSK's Affiliates, Myogen will deliver to GSK, within fifteen (15) calendar days after the end of each Calendar Quarter or reporting period as designated by CMS to include monthly, the following information: (a) the "best price" (as defined under the Social Security Act, 42 USC Section 1396r-8(c)(1)(C)) for all Product, identified by NDC number; (b) the "average manufacturer price" (AMP) (as defined under the Social Security Act, 42 USC Section 1396r-8(k)(1)) and the relevant sales dollar amount as well as the number of units applicable to each calculation for all of such Product, each identified by NDC number; (c) the "average sales price" (as defined under the Medicare Modernization Act, 42 U.S.C. Section 1395w-3); and (d) the relevant sales dollar amount as well as the number of units applicable to each calculation for all of such Product, each identified by NDC number. Myogen agrees to provide to GSK any additional data or other information required for the calculation and reporting of a government mandated price as well as the calculation of the rebates contemplated in Section 3.5. Myogen agrees that GSK may use all information described in this Section 3.6 in reporting to the CMS. GSK will provide Myogen with Medicaid pricing data required to support the continued filing for Product with the CMS after the transition to [..**..] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Myogen's NDC number, including, Base Date Average Manufacturer's Price as defined under the Medicaid Rebate Law (MRL).
Medicaid Information. The Business Associate acknowledges that all information related to the New Jersey Medicaid/NJ FamilyCare program is confidential, disclosure must be restricted to purposes directly connected with the administration of the New Jersey Medicaid/NJ FamilyCare State Plans, and Business Associate must comply with 42 C.F.R. 431.300 et seq. and N.J.A.C. 10:49-9.7. See also 42 U.S.C. 1396a(a)(7) and N.J.S.A. 30:4D-7(g). The Business Associate shall ensure that all persons who will handle or have access under this Agreement to New Jersey Medicaid/NJ FamilyCare information will be advised of the confidentiality of the records and the safeguarding requirements.
